Gut Bacteria Linked to High Blood Pressure and Depression
|
By LabMedica International staff writers Posted on 17 Sep 2019 |

Image: This infographic illustrates the connection between the brain, central nervous system and other organs and how they interact with a person\'s gut microbes to show different patterns from people with high blood pressure plus depression; high blood pressure without depression; depression with healthy blood pressure; or healthy subjects without depression or high blood pressure (Photo courtesy of Professor Bruce R. Stevens, PhD).
The microbiome is the genetic material of all the microbes, bacteria, fungi, protozoa and viruses that live on and inside the human body. The number of genes in all the microbes in one person's microbiome is 200 times the number of genes in the human genome.
A study of human gut bacteria, known as the gut microbiome, suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression. The gut may be targeted someday to prevent, diagnose and selectively treat different forms of high blood pressure with or without depression.
Scientists from the University of Florida College of Medicine (Gainesville, FL, USA) made a study of bacteria in the gut identified differences between people with high blood pressure compared to those with high blood pressure plus depression. They isolated DNA (deoxyribonucleic acid, the carrier of genetic information) from gut bacteria obtained from the stool samples of 105 volunteers. They used a new technique involving artificial-intelligence software to analyze the bacteria, which revealed four distinct types of bacterial genes and signature molecules.
Surprisingly, the investigators discovered unique patterns of bacteria from people with 1) high blood pressure plus depression; 2) high blood pressure without depression; 3) depression with healthy blood pressure; or 4) healthy subjects without depression or high blood pressure. The authors concluded that the results suggest different medical mechanisms of high blood pressure that correlate with signature molecules produced by gut bacteria. These molecules are thought to impact the cardiovascular system, metabolism, hormones and the nervous system.
Bruce R. Stevens, PhD, a Professor of Physiology & Functional Genomics, Medicine and Psychiatry and the lead author of the study, said, “People are 'meta-organisms' made up of roughly equal numbers of human cells and bacteria. Gut bacteria ecology interacts with our bodily physiology and brains, which may steer some people towards developing high blood pressure and depression. We believe we have uncovered new forms of high blood pressure: 'Depressive Hypertension' (high blood pressure with depression), which may be a completely different disease than 'Non-Depressive Hypertension' (high blood pressure without depression), which are each different from 'Non-Hypertensive Depression.” The study was presented at the American Heart Association's Hypertension 2019 Scientific Sessions on September 5, 2019, in New Orleans, LA, USA.
Related Links:
University of Florida College of Medicine
A study of human gut bacteria, known as the gut microbiome, suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression. The gut may be targeted someday to prevent, diagnose and selectively treat different forms of high blood pressure with or without depression.
Scientists from the University of Florida College of Medicine (Gainesville, FL, USA) made a study of bacteria in the gut identified differences between people with high blood pressure compared to those with high blood pressure plus depression. They isolated DNA (deoxyribonucleic acid, the carrier of genetic information) from gut bacteria obtained from the stool samples of 105 volunteers. They used a new technique involving artificial-intelligence software to analyze the bacteria, which revealed four distinct types of bacterial genes and signature molecules.
Surprisingly, the investigators discovered unique patterns of bacteria from people with 1) high blood pressure plus depression; 2) high blood pressure without depression; 3) depression with healthy blood pressure; or 4) healthy subjects without depression or high blood pressure. The authors concluded that the results suggest different medical mechanisms of high blood pressure that correlate with signature molecules produced by gut bacteria. These molecules are thought to impact the cardiovascular system, metabolism, hormones and the nervous system.
Bruce R. Stevens, PhD, a Professor of Physiology & Functional Genomics, Medicine and Psychiatry and the lead author of the study, said, “People are 'meta-organisms' made up of roughly equal numbers of human cells and bacteria. Gut bacteria ecology interacts with our bodily physiology and brains, which may steer some people towards developing high blood pressure and depression. We believe we have uncovered new forms of high blood pressure: 'Depressive Hypertension' (high blood pressure with depression), which may be a completely different disease than 'Non-Depressive Hypertension' (high blood pressure without depression), which are each different from 'Non-Hypertensive Depression.” The study was presented at the American Heart Association's Hypertension 2019 Scientific Sessions on September 5, 2019, in New Orleans, LA, USA.
Related Links:
University of Florida College of Medicine
Latest Pathology News
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
- Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Channels
Clinical Chemistry
view channel
Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more
Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
Alzheimer’s disease and related dementias develop over years, making it difficult to identify at-risk patients before symptoms appear. Clinicians therefore need widely available laboratory markers that... Read more
Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
Diagnosing malignancy from pleural effusion remains challenging because tumor cells are rare and clusters are easily disrupted during processing. Conventional cytology can miss malignant tumor cells and... Read moreMolecular Diagnostics
view channel
AI Blood Test Enhances Monitoring of Liver Cirrhosis Progression
Monitoring chronic liver disease remains difficult because clinicians rely on tools that can be inconsistent and may miss early progression. Standard approaches often combine ultrasound imaging with blood-based... Read more
Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s
Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more
Composite Blood Biomarkers Enable Early Detection of Common Cancers
Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read moreHematology
view channel
Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read morePathology
view channel
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
Microscopy images contain rich clues about cell health, but many disease-relevant morphological differences are too subtle to see and difficult to quantify consistently. Artificial intelligence (AI) has... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more







